Please note that assistive links (commonly known as "skip to links") are used throughout this site. These links are not well-supported by some mobile devices. If you are encountering difficulty using these links, please navigate around these links, or access the site on a desktop browser.
Skip to the primary content of this page Skip to the footer of this page

Q1-2023 Pharma Services Update

Skip to the end of the Expertise Menu

Q1-2023 Pharma Services Update

Despite an uncertain macroeconomic environment, recessionary fears, the war in Ukraine, and the impact of rising interest rates, M&A activity in pharma services displayed strong resiliency Q1-23, mostly led by add-on acquisitions to existing platforms. Investors remain attracted to the long-term tailwinds driving growth across outsourced pharma services including reducing costs, technological advancements, access to value-added specialty services. Certain therapeutic areas, oncology and CNS diseases for example, will likely remain popular due to a robust pipeline of R&D activity.

Provident expects M&A activity to rebound in the second half of 2023 as companies look to fill the potential growth gap from the $100B in patents set to expire by 2030.

To print and download the full Pharma Services Update report, please click below…

[holo_button icon=”/wp-content/uploads/2023/04/Q1-2023-Pharma-Services-Update-vF.pdf”” color=”#003561″ target=”blank”]PRINT/DOWNLOAD[/holo_button]